Dr. Oxnard Discusses the Circulating Cell-Free Genome Atlas Study

Geoffrey R. Oxnard, MD
Published: Sunday, Jun 03, 2018



Geoffrey R. Oxnard, MD, associate professor of medicine, Harvard Medical School, thoracic oncologist, medical oncology, Dana-Farber Cancer Institute, discusses the design and importance of the Circulating Cell-free Genome Atlas Study study in an interview with OncLive during the 2018 ASCO Annual Meeting.

Initial data from this study suggest that cell-free DNA assays can be used with a high degree of specificity to detect signs of early stage lung cancer.

Moreover, the study included 3 types of prototype sequencing assays. These included paired cfDNA and white blood cell targeted sequencing for single nucleotide variants/indels, paired cfDNA and WBC whole genome sequencing for copy number variation, and cfDNA whole genome bisulfite sequencing for methylation.

<<< 2018 ASCO Annual Meeting


Geoffrey R. Oxnard, MD, associate professor of medicine, Harvard Medical School, thoracic oncologist, medical oncology, Dana-Farber Cancer Institute, discusses the design and importance of the Circulating Cell-free Genome Atlas Study study in an interview with OncLive during the 2018 ASCO Annual Meeting.

Initial data from this study suggest that cell-free DNA assays can be used with a high degree of specificity to detect signs of early stage lung cancer.

Moreover, the study included 3 types of prototype sequencing assays. These included paired cfDNA and white blood cell targeted sequencing for single nucleotide variants/indels, paired cfDNA and WBC whole genome sequencing for copy number variation, and cfDNA whole genome bisulfite sequencing for methylation.

<<< 2018 ASCO Annual Meeting



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x